K.M. Bell-McGuinn

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Ursula A. Matulonis, Gerburg M. Wulf, William T. Barry et al. · Annals of Oncology · 2016 · 208 citations · Full text

Breast Oncology, Inhibitor Olaparib, Medicine +8

Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity

David Gallagher, Jason Konner, K.M. Bell-McGuinn et al. · Annals of Oncology · 2010 · 111 citations · Full text

Brca Mutation Status, Epithelial Ovarian Cancer, Medicine +7

Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer

M. William Audeh, R. T. Penson, Michael Friedländer et al. · Journal of Clinical Oncology · 2009 · 107 citations

Phase Ii Trial, Medicine, Cancer Management +15

Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)

R. Kristeleit, Ronnie Shapira‐Frommer, Ana Oaknin et al. · Annals of Oncology · 2016 · 24 citations · Full text

Inhibitor Rucaparib, Brca Mutation, Medicine +7

Consolidation strategies in ovarian cancer: Observations for future clinical trials

Paul Sabbatini, David R. Spriggs, Carol Aghajanian et al. · Gynecologic Oncology · 2009 · 12 citations · Full text

Medicine, Cancer Management, Gynecology +6